Skip to main content

Loading market data...

CRSP

CRISPR Therapeutics AG

NASDAQ • United states

$49.88

-$0.16

(-0.32%)

Source: Yahoo Finance · Quote time Oct 20, 2026 20:00 GMT+0000

Management
Credibility
Score

CRISPR Therapeutics AG (CRSP)

Unavailable

Quotes may be delayed

$4.82B

Market Cap

2,155,136

Volume

Unavailable

P/E Ratio

Unavailable

Div Yield

CRISPR Therapeutics AG Price Chart

Loading price history…

Management Credibility Analysis

Unavailable

Verified Management Score Unavailable

Management credibility requires sourced guidance and earnings history.

Upcoming Catalysts

Verified event feed

Verified Catalysts Unavailable

No sourced upcoming event feed is configured for this stock yet.

Company profile

No description available

Chief executive: Not disclosed
Headquarters: BAARERSTRASSE 14, ZUG
Founded: Not disclosed

📈 Company Timeline

Major business events

Positive

Negative

Neutral

19 Oct 2026

CRISPR Therapeutics AG reported A director or senior management change or compensation event

CRISPR Therapeutics AG filed an 8-K covering a director or senior management change or compensation event, supporting financial statements or exhibits.

14 Aug 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in CRISPR Therapeutics AG.

4 Aug 2026

CRISPR Therapeutics AG filed Form 10-Q

CRISPR Therapeutics AG submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.

4 Aug 2026

CRISPR Therapeutics AG reported Operating or financial results

CRISPR Therapeutics AG filed an 8-K covering operating or financial results, supporting financial statements or exhibits.

28 Jul 2026

Large-holder ownership filing

A holder reported or amended a beneficial ownership position of more than 5% in CRISPR Therapeutics AG.

Capital Structure & Financial Position

Financial strength and liquidity analysis

Cash and equivalents (USD)$291.34M

Total assets (USD)$2.65B

Total liabilities (USD)$904.22M

Shareholders' equity (USD)$1.75B

Long-term debt (USD)$586.20M

Source: SEC EDGAR company facts (opens in a new tab) Balance sheet dated 30 Jun 2026

Peer Comparison - Health Care

Company	Price	Market Cap
LLY - Eli Lilly and Company	$1,276.13 Yahoo Finance	$1.20T
JNJ - Johnson & Johnson	$256.74 Yahoo Finance	$618.71B
ABBV - AbbVie Inc.	$284.80 Yahoo Finance	$503.28B
UNH - UnitedHealth Group Incorporated	$418.43 Yahoo Finance	$375.58B
MRK - Merck & Co., Inc.	$148.55 Yahoo Finance	$366.50B

📋 Corporate Actions

Recent and upcoming corporate events

Verified Corporate Actions Unavailable

Dividend, buyback, split, and spin-off feeds are not ingested for this stock yet.

Financials

Financial statements and key metrics analysis

Quarter	Revenue (USD)	Operating income	Net income	Diluted EPS (USD)	Filed
Q2 2026	$10.18M	−$117.27M	−$91.15M	−$0.94	10-Q · 3 Aug 2026
Q1 2026	$1.46M	−$130.25M	−$122.93M	−$1.28	10-Q · 4 May 2026
Q4 2025	$864,000	−$154.76M	−$130.61M	Unavailable	10-K · 12 Feb 2026
Q3 2025	$889,000	−$132.06M	−$106.44M	−$1.17	10-Q · 10 Nov 2025
Q2 2025	$892,000	−$229.32M	−$208.55M	−$2.40	10-Q · 4 Aug 2025
Q1 2025	$865,000	−$148.42M	−$136.00M	−$1.58	10-Q · 6 May 2025

Source: SEC EDGAR company facts (opens in a new tab)

Analyst Consensus

Buy

Target: $71.85

44.0% upside potential

📈

Strong Buy

Unavailable

👍

Buy

8

⏸️

Hold

6

📉

Sell

0

14 analysts covering this stock

Source: Nasdaq analyst research (opens in a new tab) Retrieved 21 Oct 2026, 00:48 UTC Targets range 45.00–110.00 Ratings are third-party opinions, not advice.

💰 Upcoming Dividends

Next dividend payments

Verified Dividend Data Unavailable

Dividend calendar data is not ingested for this stock yet.

Guidance Evolution

Verified Guidance History Unavailable

Verified company guidance history is not ingested for this stock yet.

💼 Director Transactions

Recent insider activity

19

Oct 2026

Kulkarni Samarth

Director, Chief Executive Officer

Open-market sale

$49.78 per share

47,837 shares

16

Oct 2026

Kulkarni Samarth

Director, Chief Executive Officer

Option exercise

Unavailable per share

100,000 shares

14

Oct 2026

George Simeon

Director

Option exercise

$14.00 per share

30,000 shares

14

Oct 2026

George Simeon

Director

Open-market sale

$49.63 per share

14,514 shares

14

Oct 2026

KASINGER JAMES R.

General Counsel and Secretary

Open-market sale

$49.26 per share

1,040 shares

14

Oct 2026

Kulkarni Samarth

Director, Chief Executive Officer

Open-market sale

$49.26 per share

4,098 shares

13

Oct 2026

KASINGER JAMES R.

General Counsel and Secretary

Option exercise

Unavailable per share

2,113 shares

13

Oct 2026

Kulkarni Samarth

Director, Chief Executive Officer

Option exercise

Unavailable per share

8,333 shares

6

Oct 2026

KASINGER JAMES R.

General Counsel and Secretary

Option exercise

$13.62 per share

1,990 shares

6

Oct 2026

KASINGER JAMES R.

General Counsel and Secretary

Open-market sale

$60.04 per share

1,990 shares

Top Shareholders

Ark Investment Management Llc

9,460,939 shares

-16.376% change

6/30/2026

Blackrock, Inc.

8,348,977 shares

8.71% change

6/30/2026

Orbis Allan Gray Ltd

5,449,161 shares

-10.757% change

6/30/2026

Capital World Investors

4,749,525 shares

0.518% change

6/30/2026

State Street Corp

4,321,666 shares

8.516% change

6/30/2026

Gsk Plc

3,220,627 shares

0% change

6/30/2026

Geode Capital Management, Llc

2,509,915 shares

5.584% change

6/30/2026

Vanguard Group Inc

2,268,394 shares

-4.07% change

12/31/2025

T. Rowe Price Investment Management, Inc.

2,053,017 shares

-30.467% change

6/30/2026

Sr One Capital Management, Lp

2,038,763 shares

0% change

6/30/2026

Source: Nasdaq institutional holdings (opens in a new tab) Observed 21 Oct 2026, 00:48 UTC· 1 day ago

Research coverage and investment tools

CRISPR Therapeutics AG (CRSP) is a stock listed on the Nasdaq in the United States, in the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)). Its last price was US$49.88 on 20 Oct 2026. That is 19% of the way from its 52-week low of US$44.12 to its 52-week high of US$75.06. Its market capitalisation was US$4.82 billion at that price.

Watch Add to portfolio Set an alert Compare Position size

How position sizing works Dividend yield and total return

Quarter	Revenue	Operating income	Net income	Diluted EPS	Gross margin	Operating margin	Free cash flow	Filed
Q2 2026	$10.18M	−$117.27M	−$91.15M	−$0.94	—	-1,151.8%	−$84.15M	10-Q · 3 Aug 2026 (opens in a new tab)
Q1 2026	$1.46M	−$130.25M	−$122.93M	−$1.28	—	-8,933.3%	−$109.40M	10-Q · 4 May 2026 (opens in a new tab)
Q4 2025	$864,000	−$154.76M	−$130.61M	Unavailable	—	-17,912.5%	−$93.07M	10-K · 12 Feb 2026 (opens in a new tab)
Q3 2025	$889,000	−$132.06M	−$106.44M	−$1.17	—	-14,854.8%	−$84.71M	10-Q · 10 Nov 2025 (opens in a new tab)
Q2 2025	$892,000	−$229.32M	−$208.55M	−$2.40	—	-25,709.0%	−$114.00M	10-Q · 4 Aug 2025 (opens in a new tab)
Q1 2025	$865,000	−$148.42M	−$136.00M	−$1.58	—	-17,158.8%	−$54.15M	10-Q · 6 May 2025 (opens in a new tab)

Cash and equivalents: $291.34M
Total assets: $2.65B
Total liabilities: $904.22M
Shareholders' equity: $1.75B
Long-term debt: $586.20M

8-K · 19 Oct 2026 · Management change

CRISPR Therapeutics AG reported A director or senior management change or compensation event (opens in a new tab)

CRISPR Therapeutics AG filed an 8-K covering a director or senior management change or compensation event, supporting financial statements or exhibits.
SCHEDULE 13G/A · 14 Aug 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in CRISPR Therapeutics AG.
10-Q · 4 Aug 2026

CRISPR Therapeutics AG filed Form 10-Q (opens in a new tab)

CRISPR Therapeutics AG submitted Form 10-Q to the SEC for the period ending Jun 30, 2026.
8-K · 4 Aug 2026

CRISPR Therapeutics AG reported Operating or financial results (opens in a new tab)

CRISPR Therapeutics AG filed an 8-K covering operating or financial results, supporting financial statements or exhibits.
SCHEDULE 13G/A · 28 Jul 2026

Large-holder ownership filing (opens in a new tab)

A holder reported or amended a beneficial ownership position of more than 5% in CRISPR Therapeutics AG.

Insider	Date	Transaction	Shares	Average price	Filing
Kulkarni Samarth Director, Chief Executive Officer	19 Oct 2026	Open-market sale (S)	−47,837	$49.78	Form 4 (opens in a new tab)
Kulkarni Samarth Director, Chief Executive Officer	16 Oct 2026	Option exercise (M)	+100,000	—	Form 4 (opens in a new tab)
George Simeon Director	14 Oct 2026	Option exercise (M)	+30,000	$14.00	Form 4 (opens in a new tab)
George Simeon Director	14 Oct 2026	Open-market sale (S)	−14,514	$49.63	Form 4 (opens in a new tab)
KASINGER JAMES R. General Counsel and Secretary	14 Oct 2026	Open-market sale (S)	−1,040	$49.26	Form 4 (opens in a new tab)
Kulkarni Samarth Director, Chief Executive Officer	14 Oct 2026	Open-market sale (S)	−4,098	$49.26	Form 4 (opens in a new tab)
KASINGER JAMES R. General Counsel and Secretary	13 Oct 2026	Option exercise (M)	+2,113	—	Form 4 (opens in a new tab)
Kulkarni Samarth Director, Chief Executive Officer	13 Oct 2026	Option exercise (M)	+8,333	—	Form 4 (opens in a new tab)
KASINGER JAMES R. General Counsel and Secretary	6 Oct 2026	Option exercise (M)	+1,990	$13.62	Form 4 (opens in a new tab)
KASINGER JAMES R. General Counsel and Secretary	6 Oct 2026	Open-market sale (S)	−1,990	$60.04	Form 4 (opens in a new tab)

Institution	Report date	Shares	Change
Ark Investment Management Llc	6/30/2026	9,460,939	-16.376%
Blackrock, Inc.	6/30/2026	8,348,977	8.71%
Orbis Allan Gray Ltd	6/30/2026	5,449,161	-10.757%
Capital World Investors	6/30/2026	4,749,525	0.518%
State Street Corp	6/30/2026	4,321,666	8.516%
Gsk Plc	6/30/2026	3,220,627	0%
Geode Capital Management, Llc	6/30/2026	2,509,915	5.584%
Vanguard Group Inc	12/31/2025	2,268,394	-4.07%
T. Rowe Price Investment Management, Inc.	6/30/2026	2,053,017	-30.467%
Sr One Capital Management, Lp	6/30/2026	2,038,763	0%

Previous close: 50.04 USD
Day range: 47.36 – 50.33 USD
52-week range: 44.12 – 75.06 USD
Volume: 2,155,136
Market cap: $4.82B
Average volume: 1,563,123
EPS (FY 2025, diluted): −6.47 USD
Shares outstanding: 96.69M
Beta (5Y monthly): 1.89

Price, ranges and volume: Yahoo Finance (opens in a new tab) Observed 20 Oct 2026, 20:00 UTC· 1 day ago

Average volume, P/E and shares: Nasdaq (opens in a new tab) Observed 22 Oct 2026, 06:16 UTC· 15 minutes ago

EPS: SEC EDGAR company facts (opens in a new tab)

Beta: 5 years of monthly returns against the S&P 500, calculated from Yahoo Finance prices. Market cap is the price × shares outstanding.

This research is not available for CRSP yet

Guidance history

IMPORTANT FINANCIAL DISCLAIMER: The information provided on this platform is for educational and informational purposes only and should not be construed as investment advice. All investments involve risk, including potential loss of principal. Past performance does not guarantee future results. Take Profits is not a registered investment advisor and does not provide personalized investment advice. Users should conduct their own research and consult with qualified financial professionals before making investment decisions. Market data may be delayed and is provided by third-party sources.